Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Regeneron Pharmaceuticals — Investor Presentation (February 2022)
23 slides from Regeneron Pharmaceuticals's investor presentation, February 2022
Slide 1: Regeneron Corporate Presentation
Regeneron Corporate Presentation F e b r u a r y 2 0 2 2 This non-promotional presentation is intended for the investor audience and contains investigational data as well as forward-looking statements; actual results may vary materially
Slide 2: Note regarding forward-looking statements & non-GAAP financial measures
Note regarding forward-looking statements & non-GAAP financial measures This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events
Slide 3: Executing on Core Competencies, Investing in Regeneron, Looking Ahead
Executing on Our Investing in Looking Ahead Core Competencies Regeneron to the Future Investing $1.8 billion to Driving continued growth in expand our R&D 30+ therapeutic candidates core franchises Advancing a capabilities and in various stages of clinical best-in-class, manufacturing development *
Slide 4: Delivering Results Across the Organization
Delivering Results Across the Organization 2021 R&D Pipeline Advancements Positive Ph2 results for Aflibercept 8mg in wAMD Positive Ph3 results in four potential new indications (CSU, PN, EoE, Pediatric AD 6mo-5y) Received approval in asthma for children ages 6y-11y 4Q 2021 +17% YoY Positive chemoth
Slide 5: EYLEA: 10 Years of Patient Impact
EYLEA®: 10 Years of Patient Impact Extending leadership position based on efficacy and safety that has transformed millions of lives; 40+ million doses administered since launch Developed using our proprietary Trap technology, development on aflibercept began in 2004 and became Regeneron’s second FD
Slide 6: Dupixent: Strong Performance Across All Approved Indications
Dupixent®: Strong Performance Across All Approved Indications With Significant Opportunity For Sustained Growth ~$6.2Bn FY2021 global net product sales Net Product Sales, $Million $426 Atopic U.S. ROW $406 Dermatitis Asthma CRSwNP $352 $1,348 $1,257 $301 $246 $1,147 $926 $962 2.3M* 975k 90k Single d
Slide 7: Dupixent: Near- and Long-Term Opportunities to Drive Growth
Dupixent®: Near- and Long-Term Opportunities to Drive Growth Estimated regulatory submission timeline for new indications Up to 4M+ 2022e 2023e 2024+e Eligible Patients Eosinophilic Additional ~450k Addressable Population Additional ~425k Addressable Population Esophagitis Bullous Type 2 Pemphigoid
Slide 8: Dupixent & Itepekimab COPD Phase 3s Underway
Dupixent® & Itepekimab (anti IL-33) COPD Phase 3s Underway Two-pronged approach against uncontrolled, moderate-to-severe COPD Dupixent potential to address Type 2 COPD Achieved prespecified efficacy milestone in interim analysis of Non-Type 2 Type 2 first Ph3 study (70% of COPD patients^) Former Smo
Slide 9: Rapid Mobilization to Address COVID-19
Rapid Mobilization to Address COVID-19 If SARS-CoV2 remains endemic, we anticipate an enduring need for the immunocompromised Delta (B.1.617.2): Current REGEN-COV is active 4Q21 2021 Omicron (B.1.1.529): Next generation candidate active Doses delivered* ~1.1M ~2.8M Regulatory discussions are ongoing
Slide 10: Continued Progress & Developments Across Oncology Pipeline
Continued Progress & Developments Across Oncology Pipeline Regeneron positioned to enhance and extend treatment benefit across many cancer settings Dermato-Oncology Non-Small Cell Lung Cancer • First-in-class leading treatment for advanced CSCC • Approved in 1L advanced NSCLC • Approved in 2L+ advan
Slide 11: Regeneron's Oncology Toolkit Provides Unique Combinatorial Flexibility
Regeneron’s Oncology Toolkit Provides Unique Combinatorial Flexibility VelocImmune® Bispecifics Collaborations Antibodies Adicet Bio BioNTech CD3 Costimulatory New Classes of Vyriad Bispecifics Bispecifics Bispecifics Nykode LAG3 CD20 Lymphoma TAA METxMET ISA GITR BCMA Multiple Myeloma TAA PiGs 2sev
Slide 12: Bispecifics for Heme-Onc Malignancies: Promising Results from Maturing CD3 Programs
Bispecifics for Heme-Onc Malignancies: Promising Results from Maturing CD3 Programs Combinations with costimulatory bispecifics and other agents entering clinic soon Odronextamab (CD20xCD3) REGN5458 (BCMAxCD3) Program Update ASH 2021 Update Summary – A single, off-the-shelf bispecific, effective in
Slide 13: Bispecifics for Solid Malignancies
Bispecifics for Solid Malignancies: Potential to Extend Benefits of Checkpoint Inhibitors; Initial Data in 2022 Our footprint in oncology continues to expand Lung, Advanced Cancers Ovarian Cancer Prostate Cancer REGN5093 (METxMET) REGN4018 (MUC16xCD3) REGN5678 (PSMAxCD28) ➢ Seeing early signs of cli
Slide 14: Broad Oncology Pipeline Continues to Advance
Broad Oncology Pipeline Continues to Advance ONGOING LIBTAYO* Advanced Lung cancer (chemo combo); adjuvant CSCC REGN3767 (LAG-3) + LIBTAYO* Advanced melanoma REGN6569 (GITR) + LIBTAYO* Solid tumors REGN4018 (MUC16xCD3) + LIBTAYO* 2+ line Ovarian cancer REGN5668 (MUC16xCD28) + REGN4018 / LIBTAYO* 2+
Slide 15: Regeneron Technologies Power Our Pipeline: TRAPs, Antibodies and Bispecifics
Regeneron Technologies Power Our Pipeline: TRAPs, Antibodies and Bispecifics xxVELOCIGENE®️ TARGET DISCOVERY & TURNKEY VALIDATION THERAPEUTICS: TRAPs & ANTIBODIES VELOCIMOUSE®️ (BISPECIFICS & COSTIMS) Rubine / Marigold / White (Late 2016) Protein VELOCIMMUNE®️ Expression Sciences TECH Rubine / Marig
Slide 16: Synergistic Collaborations Supercharge Regeneron's Future
Synergistic Collaborations Supercharge Regeneron’s Future Turnkey Genetics Therapeutics Platforms Unlocking capabilities of mouse and Learnings from mouse genetics human genetics through Existing Turnkey Technologies Novel Turnkey Technologies Biologicals Gene Medicines siRNA Genome Gene TRAPs Antib
Slide 17: Regeneron Genetics Medicines
Regeneron Genetics Medicines Powerful resource linking human genetic variation to disease; empowering strategic partnerships to drive the future of medicine World leading human sequencing • ~2M human exomes sequenced • Linked to Electronic Health Records • 100+ collaborations globally Novel Genetics
Slide 18: Regeneron Genetics Medicines: 3 genetics medicines programs in the clinic
Regeneron is investing in and delivering REGENERON GENETICS technologies well beyond antibodies MEDICINES • 3 genetics medicines programs in the clinic Building the Pipeline for the Future • 3-5 additional potential targets to advance to IND-enabling studies in next 12 months Pre-IND Clinical Develo
Slide 19: Regeneron-Discovered, Approved and Investigational Medicines Across a Wide and Diverse Set of Diseases
Regeneron-Discovered, Approved and Investigational Medicines Across a Wide and Diverse Set of Diseases PHASE 1 PHASE 2 PHASE 3 APPROVED fianlimab (LAG-3) cemiplimab* (PD-1) cemiplimab* (PD-1) METxMET (REGN5093) METxMET ADC (REGN5093-M114) pozelimab + cemdisiran ‡ (C5 + C5) odronextamab (CD20xCD3) MU
Slide 20: Multiple Potential FDA Submissions: 2022-2024+
Multiple Potential FDA Submissions: 2022-2024+ 2022 2023 2024+ EYLEA DUPIXENT* Fianlimab (LAG3) + LIBTAYO Itepekimab (IL-33)* Q16W in NPDR (1H22) Bullous Pemphigoid Advanced Melanoma Chronic Obstructive Pulmonary Disease DUPIXENT* DUPIXENT* REGN4461 (LEPR) REGN1908-1909 (Feld1) Eosinophilic Esophagi
Slide 21: Key Upcoming Milestones (Next 12 Months)
Key Upcoming Milestones (Next 12 Months) EYLEA Solid Tumor Bispecifics • Ph3 data readout for Aflibercept 8mg formulation • Initial data for MUC16xCD3, PSMAxCD28 and METxMET Odronextamab (CD20xCD3) Dupixent • Complete enrollment in potentially pivotal Phase 2 in NHL • Complete regulatory submission
Slide 22: Strong Financial Position Enabling Critical Investments
Strong Financial Position Enabling Critical Investments Capital allocation priorities reflect business priorities $1.8B investment in Tarrytown R&D facilities 1. Invest in our best-in-class R&D capabilities Continued investments in manufacturing capacity 2. Pursue and fund business development Produ
Slide 23: Reconciliation of Total Revenue excluding REGEN-COV
Reconciliation of Total Revenue excluding REGEN-COV (casirivimab and imdevimab) 23 See slide 2 for additional important information regarding non-GAAP financial measures included in this presentation
Regeneron Pharmaceuticals — Investor Presentation (February 2022) on 6ix